Literature DB >> 18708190

Swine hemi-facial composite tissue allotransplantation: a model to study immune rejection.

Yur-Ren Kuo1, Hsiang-Shun Shih, Chien-Chih Lin, Chung-Cheng Huang, Johnson Chia-Shen Yang, Wen-Sheng Wu, Shigeru Goto, Chao-Long Chen, W P Andrew Lee.   

Abstract

OBJECTIVE: Partial face composite tissue allotransplantation was recently achieved in a human subject. However, the side effects of long-term immunosuppression and chronic rejection area still need concerning. This preliminary study investigated the reproducibility of swine hemi-facial transplantation for preclinical studies.
MATERIALS AND METHODS: Eleven out-bred miniature swine underwent hemi-facial transplant. The hemi-facial orthotopic transplant consisted of ear cartilage, auricular nerve, parotid gland and lymphoid tissue, muscle with surrounding hemi-facial skin paddle supplied by the carotid artery, and external jugular vein transplanted to recipient swine. Three different experimental designs were studied, as follows: group I (n = 4): autologous hemi-facial transplantation as a normal control; group II (n = 4): hemi-facial allotransplantation without treatment; group III (n = 3): hemi-facial allotransplantation with cyclosporine-A treatment for 4 wk. The transplanted face was observed daily for signs of rejection. Biopsy of donor skin, gland lymphoid tissue, and cartilage were obtained at specified predetermined time (d 7, 14, 28), or at the time of clinically evident rejection.
RESULTS: The results indicated the survival of group I following autologous hemi-facial transplant was 100% and indefinite until sacrifice. Group II without treatment as the controls revealed allograft rejection by d 7 to 28. The allograft with short-term cyclosporine-A treatment revealed delayed rejection by d 38 to 49 postoperatively. The histological examination in group I revealed abundant lymphocyte infiltration, especially in lymphoid gland and alloskin at 1 wk and sacrifice. In contrast, the cyclosporine treatment group showed no significant rejection signs in 4 wk posttransplants. These results demonstrated that lymphoid tissue and alloskin are both susceptible to early rejection.
CONCLUSION: The experimental results revealed this model is suitable to investigate the new strategies for preclinical facial allotransplantation studies. Monitoring and modulation of early rejection in alloskin and gland lymphoid tissue is a useful strategy to evaluate composite tissue allotransplantation survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708190     DOI: 10.1016/j.jss.2008.03.050

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

Review 1.  [Organ transplantation, composite tissue allotransplantation, and plastic surgery].

Authors:  K Knobloch; H O Rennekampff; M Meyer-Marcotty; A Gohritz; P M Vogt
Journal:  Chirurg       Date:  2009-06       Impact factor: 0.955

2.  Face transplant perfusion assessment using near-infrared fluorescence imaging.

Authors:  John T Nguyen; Yoshitomo Ashitate; Ian A Buchanan; Ahmed M S Ibrahim; Sylvain Gioux; Priti P Patel; John V Frangioni; Bernard T Lee
Journal:  J Surg Res       Date:  2012-04-27       Impact factor: 2.192

3.  Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model.

Authors:  Yur-Ren Kuo; Chien-Chang Chen; Shigeru Goto; Yu-Ting Huang; Chun-Ting Wang; Chia-Chun Tsai; Chao-Long Chen
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 4.  Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation.

Authors:  Yur-Ren Kuo; Chien-Chang Chen; Shigeru Goto; Pao-Yuan Lin; Fu-Chan Wei; Chao-Long Chen
Journal:  Clin Dev Immunol       Date:  2012-11-25

5.  Preclinical Animal Models in Facial Transplantation.

Authors:  Elie P Ramly; Rami S Kantar; Allyson R Alfonso; J Rodrigo Diaz-Siso; Eduardo D Rodriguez
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.